South African patients with rifampicin-resistant tuberculosis (TB) and resistance to
fluoroquinolones and/or injectable drugs (extensively drug-resistant (XDR) and preXDR-TB) …

Historically, dosing regimens for the treatment of tuberculosis (TB) have been proposed in
an empirical manner. Dose selection has often been the result of efficacy trials in which …

Tuberculosis (TB) kills more people than any other infectious disease. Challenges for
developing better treatments include the complex pathology due to within-host immune …

For rapid anti-tuberculosis (TB) drug development in vitro pharmacokinetic/
pharmacodynamic (PK/PD) models are useful in evaluating the direct interaction between …

Albumin concentration and body weight are altered in patients with multidrug‐resistant
tuberculosis (MDR‐TB) and change during the long treatment period, potentially affecting …

Pyrazinamide is a first-line tuberculosis drug with potent sterilizing activity. Variability in drug
exposure may potentially translate into suboptimal treatment responses. This systematic …

The Nix-TB clinical trial evaluated a new 6-month regimen containing three-oral-drugs;
bedaquiline (B), pretomanid (Pa) and linezolid (L)(BPaL regimen) for treatment of …

Bedaquiline (BDQ) is recommended for treatment of multidrug‐resistant tuberculosis (MDR‐
TB) for the majority of patients. Given its long terminal half‐life and safety concerns, such as …

The current treatment used for tuberculosis (TB) is lengthy and needs to be shortened and
improved. Pyrazinamide (PZA) has potent sterilizing activity and has the potential to shorten …

Background Pharmacokinetic data are needed for newly implemented anti-tuberculosis
drugs to help optimize their use. Objectives To help fill existing knowledge gaps, we …